Menu
GeneBe

ZFHX3

zinc finger homeobox 3, the group of Zinc fingers C2H2-type|ZF class homeoboxes and pseudogenes

Basic information

Region (hg38): 16:72782884-73891871

Previous symbols: [ "ATBF1", "C16orf47" ]

Links

ENSG00000140836NCBI:463OMIM:104155HGNC:777Uniprot:Q15911AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

No genCC data.

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the ZFHX3 gene.

  • Inborn genetic diseases (143 variants)
  • not provided (76 variants)
  • Neurodevelopmental disorder (6 variants)
  • not specified (4 variants)
  • Autism spectrum disorder (2 variants)
  • Intellectual disability (1 variants)
  • Prostate cancer, somatic (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the ZFHX3 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
25
clinvar
16
clinvar
43
missense
139
clinvar
14
clinvar
14
clinvar
167
nonsense
5
clinvar
5
start loss
0
frameshift
1
clinvar
1
inframe indel
2
clinvar
3
clinvar
6
clinvar
11
splice donor/acceptor (+/-2bp)
0
splice region
1
1
non coding
0
Total 0 5 144 42 36

Variants in ZFHX3

This is a list of pathogenic ClinVar variants found in the ZFHX3 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
16-72787228-T-G not specified Uncertain significance (Aug 02, 2021)2240480
16-72787301-C-T not specified Uncertain significance (Jan 30, 2024)3192975
16-72787302-G-A Likely benign (May 01, 2022)2646810
16-72787355-C-T not specified Uncertain significance (Jul 06, 2021)2234762
16-72787404-A-G ZFHX3-related disorder Benign/Likely benign (Oct 01, 2022)2646811
16-72787423-G-A not specified Uncertain significance (Jul 12, 2023)2597291
16-72787435-C-G not specified Uncertain significance (Sep 20, 2023)3192973
16-72787444-T-A not specified Uncertain significance (Aug 08, 2023)2592194
16-72787445-G-A ZFHX3-related disorder Benign (Dec 31, 2019)769903
16-72787446-G-C ZFHX3-related disorder Benign (Nov 16, 2019)3034363
16-72787477-G-A not specified Uncertain significance (May 08, 2023)2545242
16-72787482-A-C ZFHX3-related disorder Likely benign (Jul 10, 2019)3050798
16-72787494-G-C not specified Uncertain significance (Mar 31, 2023)2512258
16-72787591-G-C not specified Uncertain significance (Aug 10, 2023)2598461
16-72787627-G-A not specified Uncertain significance (Feb 27, 2024)3192972
16-72787648-G-C not specified Uncertain significance (Feb 13, 2023)2463437
16-72787693-G-C not specified Uncertain significance (Apr 25, 2022)2358560
16-72787694-AGCC-A ZFHX3-related disorder Benign (Jan 06, 2020)3057090
16-72787694-AGCCGCC-A ZFHX3-related disorder Benign (Sep 10, 2019)3034404
16-72787694-AGCCGCCGCC-A ZFHX3-related disorder Benign (Aug 05, 2019)3058928
16-72787694-A-AGCC ZFHX3-related disorder Benign (Jun 27, 2019)3056720
16-72787694-A-AGCCGCC ZFHX3-related disorder Benign (Dec 06, 2019)3037355
16-72787697-C-A not specified Uncertain significance (Apr 03, 2023)2532270
16-72787701-GCCGCCGCCGCCGCCGCCA-G ZFHX3-related disorder Benign/Likely benign (Mar 01, 2023)714560
16-72787707-GCCGCCGCCGCCA-G ZFHX3-related disorder Likely benign (May 15, 2023)3049870

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
ZFHX3protein_codingprotein_codingENST00000268489 9276814
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
1.001.39e-131257060421257480.000167
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense-1.2322792.12e+31.080.00012824335
Missense in Polyphen553640.330.863627621
Synonymous-6.3011719271.260.00006507409
Loss of Function9.52101250.08010.000006731418

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0002180.000214
Ashkenazi Jewish0.0002040.000198
East Asian0.0001840.000163
Finnish0.0001980.000185
European (Non-Finnish)0.0002260.000211
Middle Eastern0.0001840.000163
South Asian0.0002060.000163
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Transcriptional regulator which can act as an activator or a repressor. Inhibits the enhancer element of the AFP gene by binding to its AT-rich core sequence. In concert with SMAD- dependent TGF-beta signaling can repress the transcription of AFP via its interaction with SMAD2/3 (PubMed:25105025). Regulates the circadian locomotor rhythms via transcriptional activation of neuropeptidergic genes which are essential for intercellular synchrony and rhythm amplitude in the suprachiasmatic nucleus (SCN) of the brain (By similarity). Regulator of myoblasts differentiation through the binding to the AT-rich sequence of MYF6 promoter and promoter repression (PubMed:11312261). Down- regulates the MUC5AC promoter in gastric cancer (PubMed:17330845). In association with RUNX3, upregulates CDKN1A promoter activity following TGF-beta stimulation (PubMed:20599712). Inhibits estrogen receptor (ESR1) function by selectively competing with coactivator NCOA3 for binding to ESR1 in ESR1-positive breast cancer cells (PubMed:20720010). {ECO:0000250|UniProtKB:Q61329, ECO:0000269|PubMed:11312261, ECO:0000269|PubMed:17330845, ECO:0000269|PubMed:20599712, ECO:0000269|PubMed:20720010, ECO:0000269|PubMed:25105025}.;
Pathway
Signaling pathways regulating pluripotency of stem cells - Homo sapiens (human);fibrinolysis pathway;intrinsic prothrombin activation pathway;C-MYB transcription factor network;extrinsic prothrombin activation pathway (Consensus)

Recessive Scores

pRec
0.155

Intolerance Scores

loftool
0.0860
rvis_EVS
-4.26
rvis_percentile_EVS
0.12

Haploinsufficiency Scores

pHI
0.746
hipred
Y
hipred_score
0.595
ghis
0.603

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.890

Gene Damage Prediction

AllRecessiveDominant
MendelianHighHighHigh
Primary ImmunodeficiencyHighHighHigh
CancerHighHighHigh

Mouse Genome Informatics

Gene name
Zfhx3
Phenotype
neoplasm; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); renal/urinary system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); growth/size/body region phenotype; homeostasis/metabolism phenotype;

Gene ontology

Biological process
negative regulation of transcription by RNA polymerase II;regulation of transcription, DNA-templated;transcription by RNA polymerase II;brain development;muscle organ development;circadian regulation of gene expression;regulation of neuron differentiation;positive regulation of cell adhesion;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;response to transforming growth factor beta;regulation of locomotor rhythm
Cellular component
nucleus;nucleoplasm;transcription factor complex;cytoplasm;nuclear body
Molecular function
RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription repressor activity, RNA polymerase II-specific;DNA-binding transcription factor activity;protein binding;zinc ion binding;enzyme binding;transcription regulatory region DNA binding